miR-451 Is a Driver of Lipotoxic Injury in Patients with Diabetic Cardiomyopathy

MicroRNA 451 (miR-451) is emerging as a pivotal mediator of cardiac damage in experimental models of diabetic cardiomyopathy. Whether miR-451 plays a detrimental role in the human diabetic myocardium is unknown. The present study investigates miR-451’s role in patients with type 2 diabetes (T2D). We show that miR-451 is upregulated in myocardial specimens from T2D patients compared to controls without diabetes and correlates with cardiometabolic parameters, the myocardial triglyceride content and cardiac expression of lipotoxic genes as well as echocardiographic indices of left ventricular dysfunction. Calcium-binding protein 39 (Cab39)—a known target of miR-451 in mouse hearts—was downregulated in T2D patients vs. controls, and its expression negatively correlated with that of miR-451. In cultured human cardiomyocytes (CMs), Ago2 immunoprecipitation confirmed Cab39 to be a direct target of miR-451. Treatment with a high amount of glucose (25mM) and palmitic acid (PA) mimicked miR-451 upregulation and Cab39 downregulation in human CMs. These changes were associated with increased TGs and markers of lipotoxic injury, such as elevated oxidative stress levels, mitochondrial dysfunction and apoptosis. Targeting miR-451 led to restoration of Cab39 levels while rescuing diabetes-induced lipotoxic injury and metabolic dysfunction. By contrast, miR-451 overexpression recapitulated features of lipotoxic damage. Our findings indicate miR-451 to be a potential target for the prevention of myocardial lipotoxic injury in diabetes.

• Publication year

  2025

• Venue

  Cells

• Publication date

  2025-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/cells14171401PMID 40940812PMCID 12427974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF

  2025cited by this paper
• From Type 2 Diabetes Mellitus To Diabetic Cardiomyopathy – A Systematic Review On The Role Of MicroRNA

  2025cited by this paper
• Messenger RNA (mRNA) based therapeutics in transforming cardiovascular care: Progress, regulatory challenges and future perspectives.

  2025influential reference
• Dysregulated inflammation, oxidative stress, and protein quality control in diabetic HFpEF: unraveling mechanisms and therapeutic targets

  2025cited by this paper
• Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features

  2025cited by this paper
• Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies

  2024cited by this paper
• MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool

  2024cited by this paper
• Alterations in Circulating miRNA Levels after Infection with SARS-CoV-2 Could Contribute to the Development of Cardiovascular Diseases: What We Know So Far

  2023cited by this paper
• 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

  2023cited by this paper
• Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

  2023cited by this paper
• In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function

  2022cited by this paper
• Metformin: Activation of 5′ AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action

  2022cited by this paper
• MicroRNAs: diagnostic, prognostic and therapeutic role in heart failure—a review

  2022cited by this paper
• Vildagliptin Attenuates Myocardial Dysfunction and Restores Autophagy via miR-21/SPRY1/ERK in Diabetic Mice Heart

  2021cited by this paper
• Inflammation in Metabolic Cardiomyopathy

  2021influential reference
• Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study

  2020cited by this paper
• Cardiomyopathy in obesity, insulin resistance and diabetes

  2020cited by this paper
• Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

  2020cited by this paper
• From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.

  2020cited by this paper
• Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association

  2020cited by this paper
• Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma

  2020cited by this paper
• MiR-21-3p triggers cardiac fibroblasts pyroptosis in diabetic cardiac fibrosis via inhibiting androgen receptor.

  2020cited by this paper
• MiR-451 antagonist protects against cardiac fibrosis in streptozotocin-induced diabetic mouse heart.

  2019cited by this paper
• Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.

  2019cited by this paper
• Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy

  2019cited by this paper
• miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia

  2017cited by this paper
• MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart.

  2016cited by this paper
• The role of AMPK in cardiomyocyte health and survival.

  2016cited by this paper
• Lipid Use and Misuse by the Heart.

  2016cited by this paper
• Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes.

  2015cited by this paper
• MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway

  2015influential reference
• Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction.

  2011cited by this paper
• Cardiac-specific Deletion of LKB1 Leads to Hypertrophy and Dysfunction

  2009cited by this paper

• No citing papers are available for this paper.